Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type II receptor

doi:10.5493/wjem.v3.i4.100

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8919)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

479

HTML

6119

Figures (1-5)

227

Sum=6825

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1125

Download

969

Sum=2094

Nov 20, 2013 (publication date) through Jan 4, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Exp Med. Nov 20, 2013; 3(4): 100-107
Published online Nov 20, 2013. doi: 10.5493/wjem.v3.i4.100

Full Size Figure Download Figure

Figure 5 Transforming growth factor-β type II receptor binds to (-)-epigallocatechin-3-gallate. A: Proteins in the fractions were detected by staining with Coomassie Brilliant Blue. An aliquot of each fraction was blotted on polyvinylidene difluoride membrane and stained; B: The protein-containing fractions revealed in (A) were electrophoresed and Western blotting was performed using anti-Flag antibody. TGFRII: Transforming growth factor-β type II receptor.

Citation: Tabuchi M, Hayakawa S, Honda E, Ooshima K, Itoh T, Yoshida K, Park AM, Higashino H, Isemura M, Munakata H. Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type II receptor. World J Exp Med 2013; 3(4): 100-107
URL: https://www.wjgnet.com/2220-315X/full/v3/i4/100.htm
DOI: https://dx.doi.org/10.5493/wjem.v3.i4.100